# Handok Inc. clinical trials: 46 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 46 trials with Handok Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Handok Inc.: 46 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/handok-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 46
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 46, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 5, 2025 | NCT07102719 | Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers | Handok Inc. | Phase 1 | Completed | Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07102719) |
| March 21, 2025 | NCT06889350 | Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers | Handok Inc. | Phase 1 | Completed | Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06889350) |
| April 1, 2024 | NCT06339788 | Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers | Handok Inc. | Phase 1 | Completed | Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06339788) |
| January 18, 2023 | NCT05688098 | Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers | Handok Inc. | Phase 1 | Completed | Healthy Volunteers | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05688098) |
| January 18, 2023 | NCT05688085 | Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers | Handok Inc. | Phase 1 | Completed | Healthy Volunteers | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05688085) |
| December 23, 2022 | NCT05663073 | Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers | Handok Inc. | Phase 1 | Completed | Healthy Volunteers | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05663073) |
| August 17, 2022 | NCT05504239 | Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and... | Handok Inc. | Phase 3 | Completed | Type 2 Diabetes | 235 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05504239) |
| August 17, 2022 | NCT05504226 | Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg... | Handok Inc. | Phase 3 | Completed | Type 2 Diabetes | 214 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05504226) |
| July 27, 2022 | NCT05476354 | Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients | Handok Inc. | Phase 3 | Completed | Essential Hypertension | 271 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05476354) |
| July 27, 2022 | NCT05475665 | Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients | Handok Inc. | Phase 3 | Completed | Essential Hypertension | 157 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05475665) |
| June 6, 2022 | NCT05405777 | A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea | Handok Inc. | Observational | Completed | aHUS | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05405777) |
| April 20, 2022 | NCT05337683 | A Retrospective Non-Interventional Study to Evaluate the Impact of Eculizumab in Korean PNH Patients | Handok Inc. | Observational | Completed | PNH | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05337683) |
| July 30, 2020 | NCT04492033 | A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients | Handok Inc. | Phase 1/2 | Terminated | P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04492033) |
| July 28, 2020 | NCT04488978 | Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension | Handok Inc. | Phase 2 | Completed | Essential Hypertension | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04488978) |
| June 16, 2020 | NCT04431141 | Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin | Handok Inc. | Phase 1 | Completed | Type 2 Diabetes Mellitus | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04431141) |
| June 9, 2020 | NCT04421911 | A Study to Assess Efficacy and Safety of the Ketoprofen vs Diclofenac | Handok Inc. | Phase 3 | Completed | Osteoarthritis | 236 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04421911) |
| July 23, 2019 | NCT04028739 | Theracurmin vs Curcumin Bioavailability Study | Handok Inc. | Not applicable | Completed | Bioavailability | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04028739) |
| July 10, 2019 | NCT04014257 | A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies | Handok Inc. | Phase 1 | Completed | Phase 1, Solid Tumor, Adult | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04014257) |
| January 4, 2019 | NCT03793023 | Observational Study to Evaluate the Efficacy and Safety of Teneligliptin | Handok Inc. | Observational | Completed | Type 2 Diabetes Mellitus | 2,983 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03793023) |
| December 26, 2018 | NCT03787043 | A Study to Evaluate the Effect of Food on Fixed-Dose Combination of MP-513 10 mg and Metformin XR 750 mg | Handok Inc. | Phase 1 | Completed | Healthy Volunteers | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03787043) |
| December 26, 2018 | NCT03787017 | A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate Drugs | Handok Inc. | Phase 1 | Completed | Healthy Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03787017) |
| December 10, 2018 | NCT03769870 | Teneligliptin and Atorvastatin DDI Study | Handok Inc. | Phase 1 | Completed | Diabete Mellitus | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03769870) |
| April 25, 2018 | NCT03508323 | Tenelia Elderly CGMS Study(TEDDY) | Handok Inc. | Phase 4 | Completed | Type 2 Diabetes Mellitus | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03508323) |
| March 9, 2018 | NCT03460301 | Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH | Handok Inc. | Observational | Completed | PNH | 233 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03460301) |
| January 5, 2017 | NCT03011177 | Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients | Handok Inc. | Phase 4 | Completed | Type2 Diabetes Mellitus | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03011177) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 16 |
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 3 | 9 |
| Phase 4 | 10 |
| Not applicable | 1 |
| Observational | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 44 |
| Terminated | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 14 |
| Essential Hypertension | 3 |
| Diabetes Mellitus | 2 |
| Hypertension | 2 |
| Cryopyrin-Associated Periodic Syndromes | 2 |
| Arthritis, Rheumatoid | 1 |
| Urinary Bladder Neoplasms | 1 |
| Rhinitis, Allergic | 1 |
| Osteoarthritis | 1 |
| Asthma | 1 |
| Prostatic Hyperplasia | 1 |
| Pruritus | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Commercial printers in the United States](https://specstream.ai/data/businesses/commercial-printers/united-states)
- [Threads and yarns wholesalers in the United States](https://specstream.ai/data/businesses/threads-and-yarns-wholesalers/united-states)
- [Manufacturing consultants in the United States](https://specstream.ai/data/businesses/manufacturing-consultants/united-states)
- [Credit and debt counseling services in the United States](https://specstream.ai/data/businesses/credit-and-debt-counseling-services/united-states)
- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
- [Metal fabricators in the United States](https://specstream.ai/data/businesses/metal-fabricators/united-states)
